Cargando…

Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)

BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method...

Descripción completa

Detalles Bibliográficos
Autores principales: Forster, Tobias, Jäkel, Cornelia, Akbaba, Sati, Krug, David, Krempien, Robert, Uhl, Matthias, Häfner, Matthias Felix, König, Laila, Koerber, Stefan Alexander, Harrabi, Semi, Bernhardt, Denise, Behnisch, Rouven, Krisam, Johannes, Hennigs, Andre, Sohn, Christof, Heil, Jörg, Debus, Jürgen, Hörner-Rieber, Juliane
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268450/
https://www.ncbi.nlm.nih.gov/pubmed/32487184
http://dx.doi.org/10.1186/s13014-020-01581-9
_version_ 1783541619049365504
author Forster, Tobias
Jäkel, Cornelia
Akbaba, Sati
Krug, David
Krempien, Robert
Uhl, Matthias
Häfner, Matthias Felix
König, Laila
Koerber, Stefan Alexander
Harrabi, Semi
Bernhardt, Denise
Behnisch, Rouven
Krisam, Johannes
Hennigs, Andre
Sohn, Christof
Heil, Jörg
Debus, Jürgen
Hörner-Rieber, Juliane
author_facet Forster, Tobias
Jäkel, Cornelia
Akbaba, Sati
Krug, David
Krempien, Robert
Uhl, Matthias
Häfner, Matthias Felix
König, Laila
Koerber, Stefan Alexander
Harrabi, Semi
Bernhardt, Denise
Behnisch, Rouven
Krisam, Johannes
Hennigs, Andre
Sohn, Christof
Heil, Jörg
Debus, Jürgen
Hörner-Rieber, Juliane
author_sort Forster, Tobias
collection PubMed
description BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method for APBI is single-dose intraoperative radiotherapy (IORT) applied directly to the tumor bed during breast conserving surgery (BCS). The COSMOPOLITAN trial therefore aims to analyze the intensity of fatigue following single-shot IORT with electrons (IOERT) compared to conventional hypofractionated whole breast irradiation (WBI) in low risk early breast cancer patients. METHODS: This trial is conducted as a multicenter, prospective, randomized, two-arm phase II study comparing the intensity of fatigue in early-stage breast cancer (cT1cN0cM0, tumor size < 2,5 cm, ER pos. Her2neu neg., age > 50 years) treated either with WBI or APBI after BCS. Secondary outcomes investigated are tumor control, overall survival (OS), disease-free survival (DFS), acute and chronic toxicity, quality of life (QoL) and cosmesis. A total of 202 patients will be randomized into two arms: Patients in arm A will receive WBI (40.05 Gy, 15 fractions) after surgical resection, while patients in arm B will receive IOERT (21 Gy to the 90%-isodose) during BCS. Fatigue will be assessed 12 weeks post surgery with the help of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. DISCUSSION: The present trial aims to evaluate treatment response to compare single-shot intraoperative electron APBI to conventional WBI following BCS in early-stage low risk breast cancer patients. Fatigue is selected as the primary, patient-reported endpoint due its major clinical relevance. TRIAL REGISTRATION: The study is prospectively registered on February 12th, 2019: Clinicaltrials.gov, NCT03838419. “Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (COSMOPOLITAN)”. STUDY STATUS: Ongoing study. Start of recruitment was December 2019.
format Online
Article
Text
id pubmed-7268450
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-72684502020-06-07 Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419) Forster, Tobias Jäkel, Cornelia Akbaba, Sati Krug, David Krempien, Robert Uhl, Matthias Häfner, Matthias Felix König, Laila Koerber, Stefan Alexander Harrabi, Semi Bernhardt, Denise Behnisch, Rouven Krisam, Johannes Hennigs, Andre Sohn, Christof Heil, Jörg Debus, Jürgen Hörner-Rieber, Juliane Radiat Oncol Study Protocol BACKGROUND: Fatigue is one of the most common and distressing side-effects of breast cancer radiotherapy. According to current guidelines, accelerated partial breast irradiation (APBI) may be considered as an alternative treatment option for women with early-stage low-risk breast cancer. One method for APBI is single-dose intraoperative radiotherapy (IORT) applied directly to the tumor bed during breast conserving surgery (BCS). The COSMOPOLITAN trial therefore aims to analyze the intensity of fatigue following single-shot IORT with electrons (IOERT) compared to conventional hypofractionated whole breast irradiation (WBI) in low risk early breast cancer patients. METHODS: This trial is conducted as a multicenter, prospective, randomized, two-arm phase II study comparing the intensity of fatigue in early-stage breast cancer (cT1cN0cM0, tumor size < 2,5 cm, ER pos. Her2neu neg., age > 50 years) treated either with WBI or APBI after BCS. Secondary outcomes investigated are tumor control, overall survival (OS), disease-free survival (DFS), acute and chronic toxicity, quality of life (QoL) and cosmesis. A total of 202 patients will be randomized into two arms: Patients in arm A will receive WBI (40.05 Gy, 15 fractions) after surgical resection, while patients in arm B will receive IOERT (21 Gy to the 90%-isodose) during BCS. Fatigue will be assessed 12 weeks post surgery with the help of the Functional Assessment of Chronic Illness Therapy (FACIT) Fatigue Scale. DISCUSSION: The present trial aims to evaluate treatment response to compare single-shot intraoperative electron APBI to conventional WBI following BCS in early-stage low risk breast cancer patients. Fatigue is selected as the primary, patient-reported endpoint due its major clinical relevance. TRIAL REGISTRATION: The study is prospectively registered on February 12th, 2019: Clinicaltrials.gov, NCT03838419. “Intraoperative Electron Radiotherapy for Low-risk Early Breast Cancer (COSMOPOLITAN)”. STUDY STATUS: Ongoing study. Start of recruitment was December 2019. BioMed Central 2020-06-01 /pmc/articles/PMC7268450/ /pubmed/32487184 http://dx.doi.org/10.1186/s13014-020-01581-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Study Protocol
Forster, Tobias
Jäkel, Cornelia
Akbaba, Sati
Krug, David
Krempien, Robert
Uhl, Matthias
Häfner, Matthias Felix
König, Laila
Koerber, Stefan Alexander
Harrabi, Semi
Bernhardt, Denise
Behnisch, Rouven
Krisam, Johannes
Hennigs, Andre
Sohn, Christof
Heil, Jörg
Debus, Jürgen
Hörner-Rieber, Juliane
Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title_full Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title_fullStr Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title_full_unstemmed Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title_short Fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the COSMOPOLITAN trial (NCT03838419)
title_sort fatigue following radiotherapy of low-risk early breast cancer – a randomized controlled trial of intraoperative electron radiotherapy versus standard hypofractionated whole-breast radiotherapy: the cosmopolitan trial (nct03838419)
topic Study Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268450/
https://www.ncbi.nlm.nih.gov/pubmed/32487184
http://dx.doi.org/10.1186/s13014-020-01581-9
work_keys_str_mv AT forstertobias fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT jakelcornelia fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT akbabasati fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT krugdavid fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT krempienrobert fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT uhlmatthias fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT hafnermatthiasfelix fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT koniglaila fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT koerberstefanalexander fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT harrabisemi fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT bernhardtdenise fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT behnischrouven fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT krisamjohannes fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT hennigsandre fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT sohnchristof fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT heiljorg fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT debusjurgen fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419
AT hornerrieberjuliane fatiguefollowingradiotherapyoflowriskearlybreastcancerarandomizedcontrolledtrialofintraoperativeelectronradiotherapyversusstandardhypofractionatedwholebreastradiotherapythecosmopolitantrialnct03838419